18d agoThe Motley FoolBULLISH 57General
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Rezdiffra's biggest growth opportunity may still be ahead.
Archived explainer. For the current picture see today's MDGL page.
Why Is MADRIGAL PHARMACEUTI (MDGL) Stock Up Today?
By the Top Tier Newswire AI Desk · August 26, 2026 at 1:48 PM ET · reviewed against 1 wire stories
MADRIGAL PHARMACEUTI (MDGL) is up +5.39% in the latest session. Our newswire has captured 1 story on MDGL across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
MDGL stock rose 5.39% to $539.75 on Friday, driven by a positive analyst upgrade and strong earnings results. The stock opened at $510.14 and reached an intraday high of $539.89 at 1:45 PM ET before closing at $539.50. The move came as Wolfe Research upgraded the stock to Outperform and set a $605 price target.
What Happened
Madrigal Pharmaceuticals stock climbed on the back of a recent upgrade from Wolfe Research, which cited the company’s strong earnings and growth potential. The stock beat expectations in its second-quarter report, with earnings per share of $(1.99) versus an estimate of $(2.50) and revenue of $364.252 million versus an estimate of $353.178 million. Barclays also maintained its Overweight rating but lowered its price target to $962. These developments, combined with positive commentary from The Motley Fool about Rezdiffra’s long-term growth potential, contributed to the stock’s rally.
What The Data Shows
The stock has traded between $393.61 and $615.00 over the past 52 weeks and is currently trading near the upper end of that range. It has posted 22 fresh 52-week highs on August 26. The session saw volume of 0.1 million shares, or 0.3 times the 3-month daily average. Despite the recent rise, the stock remains unprofitable with a trailing twelve-month EPS of -14.22 and a net margin of -25.3%. Recent insider transactions show three sales totaling $2.2 million in the last 90 days, with the most recent on August 20.
What To Watch
Madrigal Pharmaceuticals does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further developments in its drug pipeline or regulatory approvals.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MDGL by the numbers
Last: $539.75Session: +5.39%Coverage: 1 stories / 1 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $11.8B52w: $393.61 to $615.00
The headlines behind the move
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on MDGL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier MDGL move explainers: 2026-08-26